• Type:

Stem cell therapies: public funding strategies in EU vs US vs Japan

Play

Involved in the acquitision of Bluerock Therapeutics by Bayer in 2019, as Investment Director at Leaps, Alasdair Thong is a Venture Partner with a strong expertise in iPS-derived cell therapies. Starting from a reflection on the differences in public funding strategies in Europe, North America, and Asia, he highlights the rationale behing the technological push in stem cell therapies in Asia.

Reviews for Stem cell therapies: public funding strategies in EU vs US vs Japan

There are currently no reviews for Stem cell therapies: public funding strategies in EU vs US vs Japan
Scroll to top